A股異動丨中新賽克漲停 公佈股權激勵計劃疊加高送轉潛力
格隆匯12月17日丨中新賽克(002912.SZ)漲停,報128.55元,總市值137億元。

中新賽克昨晚公告稱,公司擬推2019年限制性股票激勵計劃,激勵對象為378人,擬授予的限制性股票數量為320.16萬股,佔本計劃公告時公司股本總額10,672.00萬股的3.00%。其中,首次授予266.11萬股限制性股票,預留54.05萬股限制性股票,授予價格為58.43元/股。本計劃授予限制性股票的限售期分別為自相應授予部分股權登記完成之日起24個月、36個月、48個月。另外公司每股公積金5.05元,股本較小,有高送轉潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.